Kajian klinikal Limfoma di Illinois
23 kajian untuk Limfoma sedang mencari peserta di lokasi di Illinois.
Bandar di Illinois
Teks kajian rasmi (Bahasa Inggeris)
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07015242CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Lurie Children's Hospital-Chicago, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Mengambil pesertaFasa 1/2
12 Months – 21 Years · Semua jantina · Dikemas kini 11 Sep 2026 · NCT04870944Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Chicago
Mengambil pesertaFasa 3
Umur 18 hingga 18 · Semua jantina · Dikemas kini 8 Sep 2026 · NCT07509151A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- University of Illinois Cancer Center, Chicago
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT06624085Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- City of Hope - Chicago, Zion
Mengambil pesertaFasa 1/2
Umur 12 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT04588922Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
- University of Chicago, Chicago
- Northwestern University, Evanston
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Ogo 2026 · NCT07284433A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- University of Chicago Medical Center, Chicago
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT04104776A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- The David and Etta Jonas Center for Cellular Therapy, Chicago
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT06528301A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Northwestern, Chicago
- University of Chicago, Chicago
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Ogo 2026 · NCT07188558Mosaic Trial for Stem Cell Transplant Recipients
- Northwestern University Feinberg School of Medicine, Chicago
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Ogo 2026 · NCT06960993DALY II USA/ MB-CART2019.1 for DLBCL
- Robert H Lurie Cancer Center, Chicago
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Jul 2026 · NCT04792489A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Call for Information (Investigational Site 0024), Chicago
Mengambil pesertaFasa 1/2
6 Months – 17 Years · Semua jantina · Dikemas kini 6 Jul 2026 · NCT02332668A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Northwestern University, Chicago
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Jul 2026 · NCT05131022Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Lurie Children's Hospital-Chicago, Chicago
- Advocate Children's Hospital-Oak Lawn, Oak Lawn
- Saint Jude Midwest Affiliate, Peoria
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 18 Mei 2026 · NCT01790152CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Northwestern Memorial Hospital, Chicago
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Apr 2026 · NCT03328078The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- University of Illinois at Chicago Cancer Center, Chicago
Mengambil pesertaFasa 1/2
Umur 12 hingga 95 · Semua jantina · Dikemas kini 15 Apr 2026 · NCT04329728A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
- City of Hope Chicago, Zion
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Mac 2026 · NCT06915246A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- The University of Chicago Medical Center, Chicago
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Mac 2026 · NCT04830137CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Mac 2026 · NCT07294677Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
- University of Chicago Comprehensive Cancer Center, Chicago
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Feb 2026 · NCT05745285Avo In R/R And Previously Untreated MCL
- University of Chicago Medical Center, Chicago
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Jan 2026 · NCT04855695Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
- OSF Saint Anthony's Health Center, Alton
Mengambil pesertaFasa 3Sukarelawan sihat dialu-alukan
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Jan 2026 · NCT05006482Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
- Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2025 · NCT04234048Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.